

1 **Title**

2 A newly identified pathology of Episodic Angioedema with Hypereosinophilia (Gleich's Syndrome) revealed by Multi-
3 Omics Analysis

4

5 **Authors' Names and Affiliations**

6 Tatsuya Koreeda^a, Hirokazu Muraoka^{b,*} and Yasunori Sato^c

7

8 ^a Independent Researcher, Ikawadani-cho, Kobe-shi, Hyogo 651-2113, Japan

9 ^b CLINIC FOR Tamachi, Nagisa Terrace 4F, 3-1-32 Shibaura, Minato-ku, Tokyo 108-0023, Japan

10 ^c Department of Preventive Medicine and Public Health, School of Medicine, Keio University

11 *: correspondence

12

13 Correspondence: Hirokazu Muraoka-hirokazu_muraoka@clinicfor.life

14

15

16 **Abstract**

17 Episodic Angioedema with Eosinophilia (Gleich syndrome) is a rare disease characterized by periodic angioedema, fever,
18 and marked eosinophilia. This study aimed to elucidate the pathogenic factors of severe Gleich syndrome through
19 comprehensive multi-omics analysis, including whole genome sequencing (WGS) and RNA sequencing (RNA-seq). A
20 young female patient (age: 16-20 years old) presenting with periodic high fever, extensive urticaria/eczema, and marked
21 eosinophilia was diagnosed with Gleich syndrome. The symptoms were severe, showing no spontaneous remission, but
22 responded to oral steroid therapy with mild resolution. WGS of the patient's blood identified high-impact pathogenic
23 mutations in 16 genes, including PRDM16. RNA-seq analysis revealed differentially expressed genes (DEGs) associated
24 with immune response regulation and viral defense. Combined z-score analysis of WGS and RNA-seq data highlighted
25 ACE as a key gene, with its expression significantly downregulated during disease progression and recovered with
26 treatment. IFNG was also identified. The findings suggest that decreased ACE expression, driven by PRDM16 mutations
27 and altered IFNG expression, likely contributed to increased bradykinin levels and activation of the arachidonic acid
28 cascade, resulting in the severe inflammation and angioedema characteristic of Gleich syndrome. This study highlights
29 the utility of integrating WGS and RNA-seq data to uncover the molecular basis of rare diseases and provides a
30 foundation for developing therapeutic strategies for hypereosinophilic syndromes.

31

32 **Keywords**

33 Eosinophilia;

34 Gleich syndrome;

35 Hypereosinophilic syndrome;

36 Episodic Angioedema with Eosinophilia;

37 Whole genome sequence;

38 RNA sequence;

39 Multi-omics analysis;

40

41

42 **Introduction**

43 Eosinophilia is defined as a condition characterized by an absolute eosinophil count in the peripheral blood exceeding
44 500 cells/ μ L [1,2]. Hypereosinophilia (HE) is defined as: 1) an absolute eosinophil count in the peripheral blood
45 exceeding 1500 cells/ μ L in two blood samples taken at least 4 weeks apart; and/or 2) evidence of hypereosinophilia in
46 tissues, which includes one or more of the following criteria: a) eosinophils constituting more than 20% of the total
47 nucleated cells in the bone marrow; b) an abnormally intense eosinophilic infiltration in tissues as assessed by a
48 pathologist; or c) extensive deposition of eosinophil granule proteins identified by special staining techniques [3].
49 Hypereosinophilic syndrome (HES) is defined by the following criteria: 1) the criteria for HE are met, 2) there is organ
50 damage caused by peripheral tissue hypereosinophilia, and 3) other conditions that could cause organ damage have been
51 excluded [3]. Another syndrome associated with HE is angioedema with eosinophilia, also known as Gleich syndrome.
52 This rare clinical entity was first described by Gerald Gleich in 1984 and is characterized by angioedema with marked
53 eosinophilia, accompanied by fever, periodic weight gain, and urticaria [4]. Hypereosinophilic syndrome (HES) was first
54 proposed as a disease concept by Hardy and Anderson in 1968, with diagnostic criteria later developed by Chusid et al. in
55 1975. Initially, it was considered a syndrome encompassing many conditions diagnosed primarily by exclusion. Since
56 then, the causes of some conditions previously classified as HES have been clarified [5,6], but many remain unexplained.
57 The same applies to hypereosinophilia (HE), including Gleich syndrome. The same is true for HE, including Gleich
58 syndrome. The low prevalence of HE and HES, combined with the need to initiate treatment before confirming strict
59 diagnostic criteria, has left many aspects of these diseases medically unexplored.

60 In recent years, genomic analysis technologies, including Whole Genome Sequencing (WGS), Whole Exome
61 Sequencing (WES), and targeted sequencing, have gained attention as research tools for elucidating the causes and
62 mechanisms of diseases [7]. By comprehensively analyzing the entire spectrum of genetic variation, this technology can
63 identify etiological genes and associated factors that are challenging to detect using conventional methods. WGS is
64 particularly effective in the study of rare diseases, where many pathologies are strongly influenced by genetic factors [8–
65 10]. In HE and HES, somatic mutations in haematopoietic cells have been investigated using targeted sequencing, as well
66 as the relationship between clonal proliferation of eosinophils and novel disease-related mutations, using WES [11,12].
67 However, knowledge about the genetic background and mechanisms underlying the pathogenesis of HE and HES
68 remains limited, as their causes are still unknown, and few cases have been analyzed using WGS. The aim of this study
69 was to identify pathological factors in patients diagnosed with HE/Gleich syndrome of unknown etiology. We

70 investigated the pathological factors of idiopathic hypereosinophilia by analyzing WGS and RNA-seq data obtained from

71 these patients.

72

73 **Materials and Methods**

74 **Patient**

75 Patient with disease onset from April 2022 and diagnosed with severe Gleich syndrome in July 2023 was evaluated. The
76 following clinical and laboratory information was collected: gender, age of onset, imaging evaluation of trunk organs and
77 musculature, pathology of enlarged lymph nodes, pathology of skin lesions, peripheral blood counts including absolute
78 eosinophil count, general biochemical tests, immunological tests, genetic tests, allergy tests, and parasite tests. The study
79 protocol was approved by the Ethics Committees of the Clinic for Tamachi in Tokyo (approval number: CFT20230727),
80 Japan, and all participants provided written informed consent.

81

82 **Sample Collection**

83 Whole blood samples (2 mL) were collected from one patient and three healthy subjects. DNA and RNA were extracted
84 simultaneously from the patient's samples, which were collected at three time points: before treatment initiation, 30 days
85 after treatment initiation, and 90 days after treatment initiation. The collected whole blood samples were used for
86 subsequent WGS and RNA-seq analyses. The analysis workflow is provided in the Supplementary Information 1 (Figure
87 S1).

88

89 **WGS Processing and Sequencing**

90 Nucleic acids were extracted using the NucleoSpin RNA Blood Kit and NucleoSpin RNA/DNA Buffer Set from
91 MACHEREY-NAGEL, following the manufacturer's recommended protocol. In this process, genomic DNA was eluted
92 first, followed by the extraction of total RNA. The extracted RNA was purified using the NucleoSpin RNA Clean-up XS
93 Kit. The quality of the nucleic acid samples was assessed using Agilent Technologies' TapeStation or BioAnalyzer. This
94 assessment included double-stranded DNA quantification, agarose gel electrophoresis, and purification steps. The final
95 quality assessment was based on the results from these instruments. Sequence libraries were prepared using Illumina's
96 TruSeq DNA PCR-Free Library Prep Kit and IDT for Illumina - TruSeq DNA UD Indexes v2. DNA was fragmented into
97 hundreds of base pairs using Covaris Acoustic Solubilisers, followed by end-repair and phosphorylation. After size
98 selection using magnetic beads, sequence libraries were constructed through 3' dA tailing and ligation of indexed
99 adaptors. Library quality was tested using Illumina's MiSeq or iSeq systems to assess library size and concentration.
100 Sequence analysis was performed on Illumina's NovaSeq X Plus system using the NovaSeq X Series 10B Reagent Kit

101 and accompanying control software. Cluster generation and sequencing were conducted with Real Time Analysis (RTA)
102 v4.6.2 and bclfastq2 v2.20 software.

103

104 **RNA-seq Processing and Sequencing**

105 Nucleic acids were extracted from the provided samples using MACHEREY-NAGEL's NucleoSpin RNA Blood Kit, and
106 electrophoretic quantification was performed using a TapeStation or BioAnalyzer (Agilent Technologies) to assess the
107 quality and quantity of the nucleic acids. Globin-depleted RNA samples were used, and adaptor sequences were added to
108 both ends of the first-strand cDNA using the SMART method. PCR amplification was then performed using primers
109 recognizing the adaptor sequence, and the PCR products were purified with AMPure XP (Beckman Coulter). The double-
110 stranded cDNA was fragmented by a transposon-based tagging reaction, followed by the addition of adaptor sequences.
111 Next, PCR amplification was carried out using indexed primers with distinct tag sequences to create a sequencing library.
112 The quality of the library was assessed using an electrophoresis system. Reagent details for library preparation are
113 provided in the data sheet. The processed samples underwent 150 base pair paired-end sequencing analysis using the
114 NovaSeq system, and the raw data were converted to FASTQ file format using the provided software.

115

116 **Mapping Genomic Variation and Adding Annotation Information**

117 Genomic mutation analysis was conducted using the DRAGEN Bio-IT Platform (Illumina). First, sequencing reads were
118 mapped to the reference genome (hg38 decoy). Duplicates were marked, and these marked reads were used to identify
119 candidate mutant bases, including single nucleotide substitutions and short insertions/deletions, that differ from the
120 reference sequence. For multiple samples, the detection results were merged. The detected mutant bases were then
121 filtered, and SnpEff and vcftools were used to assess the impact of the mutations. This assessment included comparing
122 the candidate mutant bases with gene structure, predicting the impact of missense mutations (using FATHMM scores
123 from dbNSFP), evaluating the mutation's frequency across populations in gnomAD and East Asian allele frequencies,
124 and adding clinical significance annotations from ClinVar.

125

126 **Variant Filtering and Analysis Workflow**

127 Variant analysis was performed using SnpSift (version 4.3t) for filtering variants. Filtering criteria were restricted to
128 variants with a total depth (DP) of 25 or greater to eliminate low-quality variants. Pathogenic SNVs were then extracted,
129 focusing on those with annotation impacts labeled as HIGH and MODERATE. The filtered variants were analyzed to

130 extract SNVs, Indels, and Structural Variants (SVs). The tools used for this analysis included AnnotSV [15],
131 wANNOVAR [16], and SNPnexus [17]. AnnotSV used VCF files filtered by total depth and extracted variants with a
132 class of 3 or higher in the ACMG guideline column. wANNOVAR focused on exonic regions, while SNPnexus excluded
133 SNPs labeled 'Benign' and 'Likely Benign' in the ClinVar column. Data tables were generated from each tool, and
134 columns without values were manually excluded upon inspection. Snowflake was utilized to examine the variants
135 directly from the VCF files: after creating the database and schema in Snowflake, the VCF files were uploaded to an
136 internal stage using SnowSQL (Version 1.2.32). The data were then loaded as semi-structured data into tables, and SQL
137 was used for filtering.

138

139 **Mapping and Counting of Read Sequences**

140 In the RNA sequencing analysis, read sequences were mapped to the human reference genome GRCh38 using Illumina's
141 NovaSeq Control Software version 1.7.5. Following mapping, quality control of the sequence data was performed using
142 Illumina's Real Time Analysis (RTA) software version 3.4.4. The resulting BCL files were converted to FASTQ format
143 using bcl2fastq2 version 2.20. For mapping, a gene definition file based on GENCODE version 39 was used,
144 incorporating detailed gene structures and annotation information. Annotation information was then added to the
145 mapping data, and expression levels were organized in a tabular format. This process was conducted using Illumina's
146 DRAGEN Bio-IT Platform version 3.7.5, with the software's default parameters applied at each step, from mapping read
147 sequences to gene expression analysis. The resulting count data were used for subsequent gene expression analyses.

148

149 **Analysis of Established Gene Expression Levels Using RNA-Seq Data**

150 Gene expression levels were analyzed using RNA-seq count data, focusing on genes labeled as 'protein_coding' before
151 extracting Differentially Expressed Genes (DEGs). DESeq2 (Version 1.40.2) was used to identify DEGs by comparing the
152 patient samples with those of three healthy subjects. Pathway enrichment analysis and protein-protein interaction (PPI)
153 network analysis were performed on the identified DEGs. The pathway enrichment analysis was based on data from the
154 GO term and KEGG databases. GO enrichment analysis classified the DEGs into three functional groups: biological
155 processes, cellular components, and molecular functions [13]. The PPI network analysis was conducted using the
156 STRING database in Cytoscape, with a Confidence Score cutoff of >0.7 and a maximum of 30 additional interactors. To
157 identify hub genes, PPIs with a Confidence Score cutoff of >0.95 were screened, and the centrality of each gene in the

158 PPI network was calculated using the CentiScaPe 2.2 plugin. Heatmaps were generated using the heatmap (Version
159 1.0.12) package.

160

161 **Integrated Variant and Gene Expression Analysis with Z-Score Standardization**

162 After excluding low-quality variants and extracting those labeled as HIGH and MODERATE for annotation impact, the
163 variants were matched with RNA-seq data based on transcript ID. Variants were then filtered to include only those with
164 adjusted p-values less than 0.05 and an absolute Fold Change greater than 2. The PPI network centrality score was
165 quantified using Centiscape 2.2. Following standardization by z-score based on adjusted p-values, absolute Fold Change,
166 and centrality score values, the z-score totals were calculated for each gene.

167

168 **Ingenuity Pathway Analysis of RNA-Seq Data for Upstream and Causal Regulator Identification**

169 Ingenuity Pathway Analysis (IPA) Expression Analysis RNA-seq data files were imported into IPA, with the
170 log2FoldChange and padj columns mapped as 'Expr Log Ratio' and 'Expr p-value,' respectively. The analysis was
171 performed with a Log Ratio cut-off range of -2.32 to 2.32 and an Expr p-value cut-off of 0.05. Within the Expression
172 Analysis, Upstream Analysis was conducted to identify Upstream Regulators and Causal Regulators associated with the
173 ACE gene. For Upstream Regulators, the absolute value of the Activation Z-score for each upstream gene was mapped to
174 Target Molecules. For Causal Networks, intracellular pathway diagrams were created by generating networks for IFNG
175 genes and selecting SubCellular layouts. Disease pathway information for Angioedema and Eosinophilia was also
176 visualized under 'Disease and Functions'.

177

178

179 **Results**

180 **Clinical Findings**

181 A young female patient (age: 16-20 years old) experienced periodic episodes of fever and myalgia, with temperatures
182 ranging from 38-40°C, accompanied by chills and shivering, occurring one or two times a month since April 2022.

183 Around October of the same year, she developed edema, urticaria, and a generalized skin rash that left pigmentation.

184 Blood tests from this period revealed markedly increased eosinophilia. During febrile episodes, the patient exhibited
185 transient neutrophil predominance and significantly elevated CRP levels. Thorough examinations were conducted at the
186 Clinic Fore Tamachi and Gunma University Hospital. A repeated clinical examinations revealed a total white blood cell
187 count of 19,200/ μ L, with an eosinophil count of 16.4% (3148/ μ L). Hemoglobin and platelet counts were normal limits.

188 Total IgE was elevated at 504 IU/mL, but specific IgE levels for common grass and tree pollens, mites, animal
189 dander, molds, and foods were within normal limits or negative. The patient, having been exposed to formalin, underwent
190 a skin test for formalin sensitivity, which was negative. Screening for parasitic antibodies was also negative.

191 Rheumatoid factor, anti-nuclear antibodies, anti-ARS antibodies, MPO-ANCA, PR3-ANCA, IgG, IgA, IgM,
192 C3, C4, and CH50 were all within normal limits. A peripheral blood smear examination revealed no morphological
193 abnormalities. Lymphocyte surface marker tests showed the following: CD7 at 56.9%, CD3 at 44.7%, CD2 at 59.3%,
194 CD4(-)CD8(+) at 9.3%, CD4(-)CD8(-) at 48.8%, CD4(+)CD8(+) at 41.2%, CD4(+)CD8(-) at 0.7%, and a CD4/CD8
195 ratio of 4.19.

196 Various imaging studies, including CT and MRI, did not reveal any tumorous lesions. However, imaging showed
197 enlarged axillary lymph nodes, splenomegaly, myositis centered around both shoulders, and bilateral pleural effusions.
198 The sIL-2R level was elevated at 1668 U/mL, but the pathology of the enlarged lymph nodes indicated dermatopathic
199 lymphadenopathy, without evidence of lymphoma or malignancy, including immunostaining results. Pathological
200 examination of the skin tissue raised a suspicion of vasculitis, though this was not definitive.

201 Genetic testing results were negative for the FIP1L1-PDGFR α fusion gene, PDGFB split signal, FGFR1 split signal, and
202 MEFV gene mutation, with no clonal gene rearrangement detected in the T-cell receptor beta chain C β 1. A summary of
203 the clinical and laboratory information is provided below, and full test results are available in the Supplementary file
204 (Supplementary Information 2).

205

206

Clinical Parameter	Patient's Data	Normal Range
--------------------	----------------	--------------

Gender	Female	-
Age of onset (years)	16-20	-
Age at diagnosis (years)	16-20	-
Symptoms	Angioedema Urticaria Pruritus Periodic fever Skin rash that leaves hyperpigmentation Muscle pain Splenomegaly Lymphadenopathy	-
Serum total IgM (mg/dL)	136	46 ~ 260
Serum total IgG (mg/dL)	1384	870 ~ 1700
Serum total IgA (mg/dL)	106	110 ~ 410
Serum total IgE (IU/mL)	504	≤170
Aberrant T-cell population	No	-
CRP (mg/dL)	17.2	≤0.14
sIL-2R (U/mL)	1668	157 ~ 474
ANA (Titer)	<1:40	<1:40
MPO-ANCA (U/mL)	<1.0	<3.5
PR3-ANCA (U/mL)	<1.0	<3.5
C3 (mg/dL)	114	86 ~ 160
C4 (mg/dL)	22	17 ~ 45
anti-ARS antibodies (Index)	<5.0	<25
EBV DNA	Not detected	-
Trunk/Maxillofacial CT	Splenomegaly Enlarged axillary lymph nodes	-
Trunk/Maxillofacial MRI	Suspected myositis around both shoulders Reactive swelling of cervical and submandibular lymph nodes Small amount of pleural effusion	-
Left axillary lymph node biopsy	Findings suggestive of dermatopathic lymphadenopathy No lymphoma or malignant findings	-
Skin biopsy	Possible vasculitis (unclear)	-
FIP1L1-PDGFR α fusion gene	Negative	-

PDGFB split signal	Negative	-
FGFR1 split signal	Negative	-
MEFV gene mutations	Negative	-

207 **Table 1 : Characteristics of the studied patient**

208

209 Based on these results and the exclusion of autoimmune and hematological disorders and secondary eosinophilia, the
210 patient was diagnosed with Episodic Angioedema with Hypereosinophilia (Gleich's Syndrome). Treatment was initiated
211 in July 2023 with oral glucocorticoids (prednisolone 30 mg/day), with subsequent tapering scheduled to the current
212 maintenance dose of 1 mg/day. The patient achieved clinical and biological remission, generally by 30 days after
213 treatment initiation and almost complete remission by 90 days.

214

215 **WGS-Based Identification of Patient-Specific Genetic Variants and Associated Mutations**

216 Patient-specific genetic variants were analyzed using WGS for diagnostic purposes. Three variant analysis tools—
217 AnnotSV, SNPnexus, and wANNOVAR — were employed. The AnnotSV analysis was filtered to include only variants
218 classified with an ACMG classes of 3 or higher (Table 2). As a result, 26 variants with an ACMG class of 3 were
219 identified, with no variants classified as more severe. Further filtering using a LOEUF_bin score of 0 identified deletion
220 mutations in the FOXO1, PRDM16, SPAST, ITSN1, and DLGAP2 genes. Mutations in FOXO1 gene have been
221 previously associated with rhabdomyosarcoma, a type of cancer. Variants in the PRDM16 gene have been linked to
222 various cancers. Mutations in the SPAST gene are known to cause neurological disorders, particularly hereditary spastic
223 paraplegia. However, no disease associations were identified for mutations in ITSN1 and DLGAP2 genes.

224

225

226

227

228

229

Gene	Chr	Range	Loc	MOI	GenCC_disease	OMIM_phenotype
FOXO1	13	40661542-40661624	CDS		-	Alveolar Rhabdomyosarcoma
PRDM16	1	3299300-3299421	CDS	AD	dilated cardiomyopathy, familial isolated dilated cardiomyopathy, left ventricular noncompaction, left ventricular noncompaction 8	Dilated Cardiomyopathy, Left ventricular noncompaction 8
PRDM16	1	3325997-3326054	CDS	AD	dilated cardiomyopathy, familial isolated dilated cardiomyopathy, left ventricular noncompaction, left ventricular noncompaction 8	Dilated Cardiomyopathy Left ventricular noncompaction 8
SPAST	2	32111248-32111315	CDS	AD;AR	Charlevoix-Saguenay spastic ataxia, hereditary spastic paraplegia 4	Spastic paraplegia 4
ITSN1	21	33876194-33876246	CDS		-	-
DLGAP2	8	999891-999994	UTR	AD	complex neurodevelopmental disorder	-

230 **Table 2 : Analysis of SVs Utilizing AnnotSV**

231

232 In the SNPnexus-based analysis, the genes were listed as pathogenic according to ClinVar annotations (Table 3).

233 The analysis identified the following relevant mutations and corresponding genes: PTPRJ (rs1566734), SLC4A1

234 (rs121912749), FGFR4 (rs351855), and C1GALT1C1 (rs17261572). In PTPRJ, a non-synonymous SNV (A/C) was

235 found at position 44,260,501 on chromosome 17, causing an amino acid change from Q276P and associated with

236 carcinoma of the colon. In SLC4A1, a non-synonymous SNV (G/A) was observed in the intron region at position

237 177,093,242 on chromosome 5, resulting in an amino acid change to G388R, suggesting an association with cancer

238 progression and tumor cell proliferation. A non-synonymous SNV (A/T) was identified in C1GALT1C1 at position

239 120,626,774 on the X chromosome, causing an amino acid change to D131E, and was associated with polyagglutinable

240 erythrocyte syndrome.

Gene	Chr	Region	Position	SNV	AA Change	ClinVar
PTPRJ	11	coding	48123823	A/C	Q276P	Carcinoma of colon
SLC4A1	17	coding	44260501	C/T	G130R	Spherocytosis type 4
FGFR4	5	intronic	177093242	G/A	G388R	Cancer progression and tumor cell motility

C1GALT1C1 X coding 120626774 A/T D131E Polyagglutinable erythrocyte syndrome

241

242 **Table 3 : Analysis of SNVs Utilizing SNPnexus**

243

244 In wANNOVAR, we identified a series of mutations across diverse genes, focusing on exonic regions (Table 4). As a
 245 result, we detected two distinct frameshift mutations across multiple exons (14, 16, and 17) in the APC gene. These
 246 mutations were identified as c.5400delT (p.N1800Kfs45), c.5454delT (p.N1818Kfs45), c.5399_5400del (p.N1800Kfs7),
 247 and c.5453_5454del (p.N1818Kfs7), all of which were heterozygous. In OR13C8, a c.242delT mutation in exon 1
 248 (p.A83Pfs6) was observed in a homozygous form, and in PCDH17, a c.237_238del mutation (p.D80Qfs78) was found in
 249 exon 1, also in a homozygous form. For GSPT1, multiple frameshift mutations were identified in exon 15, including
 250 c.1902_1909del (p.K635Sfs63), c.1491_1498del (p.K498Sfs63), and c.1905_1912del (p.K636Sfs*63), all of which were
 251 homozygous. In MED1, two heterozygous frameshift mutations were identified in exon 17, c.3210delA (p.T1071Qfs2)
 252 and c.3210_3211del (p.T1071Sfs28). In SLC35G4, synonymous SNVs c.C570T and c.C570C were detected in exon 1,
 253 both heterozygous, indicating no change in the amino acid sequence of the protein (p.G190G). In exon 4 of MADCAM1,
 254 a non-synonymous SNV, c.T718C (p.S240P), was identified in a heterozygous form.

255

Chr	Position	Exon	SNV	Gene	Exonic Func	Zygosity	HGVS
chr5	112176745	exon14, exon16, exon17	T/-	APC	frameshift deletion	het	c.5400delT(p.N1800Kfs*45), c.5399_5400del(p.N1800Kfs*7), c.5454delT(p.N1818Kfs*45), c.5453_5454del(p.N1818Kfs*7)
chr9	107331690	exon1	A/-	OR13C8	frameshift deletion	hom	c.242delT(p.A83Pfs*6)
chr13	58206917	exon1	T/-	PCDH17	frameshift deletion	hom	c.237_238del(p.D80Qfs*78)
chr16	11966978	exon15	A/-	GSPT1	frameshift deletion	hom	c.1902_1909del(p.K635Sfs*63), c.1491_1498del(p.K498Sfs*63), c.1905_1912del(p.K636Sfs*63)
chr17	37565264	exon17	A/-	MED1	frameshift deletion	het	c.3210delA(p.T1071Qfs*2), c.3210_3211del(p.T1071Sfs*28)
chr18	11610164	exon1	G/T	SLC35G4	synonymous SNV	het	c.C570T(p.G190G)
chr18	11610164	exon1	G/C	SLC35G4	synonymous SNV	het	c.C570C(p.G190G)

chr19:501719 exon4 T/C MADCAM1 nonsynonymous SNV het c.T718C(p.S240P)

256


257 **Table 4 : Analysis of SNVs Utilizing wANNOVAR**

258

259 **Enrichment Analysis and PPI Network Analysis Utilizing RNA-seq DEGs**

260 The DEGs identified from the RNA-seq data in healthy subjects and patients were further analyzed using GO
261 and KEGG pathway analyses. Upregulated genes were significantly enriched in the biological process categories of
262 ‘regulation of response to biotic stimulus’ and ‘response to virus,’ as well as in the molecular function categories of
263 ‘DNA-binding transcription factor binding’ and ‘carbohydrate binding.’ These genes were also significantly enriched in
264 the cellular component categories of ‘endocytic vesicle’ and ‘specific granule’ (Figure 1a and Table 5). Conversely,
265 downregulated genes were significantly enriched in the biological process categories of ‘leukocyte-mediated immunity’
266 and ‘cell killing,’ in the molecular function categories of ‘carbohydrate binding’ and ‘immune receptor activity,’ and in
267 the cellular component categories of ‘external side of plasma membrane’ and ‘endoplasmic reticulum lumen’ (Figure 1b
268 and Table 6). Additionally, KEGG pathway analysis revealed that the most significantly enriched gene pathways were
269 those associated with the ‘PI3K-Akt signaling pathway’ and ‘Human papillomavirus infection’ (Figure 1c).

270 Next, a PPI network analysis was performed using the DEGs. In the PPI network, which consisted of 185 DEGs,
271 214 nodes and 676 edges were mapped based on protein-protein interactions with interaction scores greater than 0.7
272 (Figure 1d). Using an interaction score greater than 0.95 to identify hub genes, the most highly connected hub genes were
273 RSAD2 (degree = 9), MX1 (degree = 8), ISG15 (degree = 8), and IFI44L (degree = 7). A heatmap of the DEGs and a
274 volcano plot showing the time-series changes in each gene expression level are provided in the Supplementary
275 Information 1 (Figure S2).



276

277 Figure 1. Pathway Enrichment Analysis Utilizing GO and KEGG, and PPI Network Analysis

278 Pathway enrichment analysis using GO and KEGG terms, and PPI network analysis based on patient RNA-seq data. a)

279 Pathway enrichment analysis using GO terms for DEGs of patient-derived upregulated genes in biological process (BP),

280 molecular function (MF), and cellular component (CC) categories. The top 10 terms in each category are shown. b)
 281 Pathway enrichment analysis using GO terms for DEGs of patient-derived downregulated genes. c) Pathway enrichment
 282 analysis using KEGG terms for DEGs of patient-derived genes with variable expression. d) Pathway enrichment analysis
 283 using GO terms for DEGs of patient-derived genes with variable expression. The vertical axis represents the percentage
 284 of DEGs in each term. e) PPI network analysis using DEGs of patient-derived genes with variable expression. Red circles
 285 represent nodes, and blue lines represent edges.
 286

Category	Term	Description	Count	%	p.adjust
BP	GO:0051607	defense response to virus	47	9.69072165	8.65E-20
BP	GO:0140546	defense response to symbiont	47	9.69072165	8.65E-20
BP	GO:0009615	response to virus	53	10.9278351	3.64E-19
BP	GO:0002831	regulation of response to biotic stimulus	55	11.3402062	3.14E-18
BP	GO:0045088	regulation of innate immune response	47	9.69072165	2.09E-16
BP	GO:1903900	regulation of viral life cycle	30	6.18556701	3.82E-16
MF	GO:0003725	double-stranded RNA binding	11	2.2	0.00202485
MF	GO:0030246	carbohydrate binding	22	4.4	0.00202485
MF	GO:0046935	1-phosphatidylinositol-3-kinase regulator activity	6	1.2	0.00202485
MF	GO:0035014	phosphatidylinositol 3-kinase regulator activity	6	1.2	0.00389573
MF	GO:0140297	DNA-binding transcription factor binding	28	5.6	0.01965112
MF	GO:0005536	glucose binding	4	0.8	0.01965112
CC	GO:0042581	specific granule	17	3.37301587	0.00036595
CC	GO:0045335	phagocytic vesicle	15	2.97619048	0.00078833
CC	GO:0070820	tertiary granule	15	2.97619048	0.00329658
CC	GO:0030139	endocytic vesicle	23	4.56349206	0.00399692
CC	GO:0005811	lipid droplet	11	2.18253968	0.00446821
CC	GO:0005942	phosphatidylinositol 3-kinase complex	6	1.19047619	0.00446821

287

288 **Table 5 : Enrichment Analysis Using Upregulated Genes Derived from RNA-seq Data**

289

Category	Term	Description	Count	%	p.adjust
BP	GO:0002228	natural killer cell mediated immunity	25	5.08130081	5.55E-17
BP	GO:0001909	leukocyte mediated cytotoxicity	31	6.30081301	6.45E-17
BP	GO:0042267	natural killer cell mediated cytotoxicity	24	4.87804878	1.16E-16
BP	GO:0002443	leukocyte mediated immunity	48	9.75609756	1.62E-15
BP	GO:0001906	cell killing	34	6.91056911	1.98E-15
BP	GO:0002449	lymphocyte mediated immunity	41	8.33333333	3.27E-15
MF	GO:0140375	immune receptor activity	21	4.1749503	1.84E-07
MF	GO:0015026	coreceptor activity	11	2.18687873	1.79E-05
MF	GO:0042287	MHC protein binding	9	1.78926441	0.00033639
MF	GO:0030246	carbohydrate binding	23	4.57256461	0.00033639
MF	GO:0043394	proteoglycan binding	8	1.59045726	0.00062812
MF	GO:0050840	extracellular matrix binding	9	1.78926441	0.00189935
CC	GO:0009897	external side of plasma membrane	36	7.10059172	2.48E-07
CC	GO:0044194	cytolytic granule	5	0.98619329	0.00211125
CC	GO:0045178	basal part of cell	21	4.14201183	0.00211125
CC	GO:0009925	basal plasma membrane	20	3.94477318	0.00211125
CC	GO:0005788	endoplasmic reticulum lumen	22	4.33925049	0.00211125
CC	GO:0016323	basolateral plasma membrane	18	3.55029586	0.00310627

290

291

292

293

Table 6 : Enrichment Analysis Using Downregulated Genes Derived from RNA-seq Data

294

295 Identification of Key Genes Utilizing Z-Score Analysis

296 Variants from WGS data labeled as HIGH in annotation impact, along with gene expression levels from RNA-seq data

297 and centrality scores from PPI network analysis, were evaluated utilizing z-score analysis (Table 7). Among the Z-scores,

298 IFI27 had the highest value (Z-Score: 4.47619923). OAS2 (Degree: 19) and ACE (ABS_log2FC: 9.10262032) exhibited

299 the highest centrality score and absolute log2 fold change, respectively. The smallest adjusted p-value was observed for

300 IFI27 (padj: 4.18E-65). The effects of the mutations were as follows: splice acceptor variant & intron variant in three
 301 cases, start lost & conservative inframe deletion in one case, frameshift variant in three cases, stop lost in one case, stop
 302 gained in two cases, and splice donor variant & intron variant in one case. Z-score values were utilized for GO term and
 303 KEGG pathway enrichment analysis as well as PPI network analysis (Figure S3). The plots of Effect Type count values
 304 for genomic variants in this patient are provided in the Supplementary Information (Figure S4).

Gene	POS	Variant	Effect	Degree	ABS_log2FC	padj	Z_Score
IFI27	14:94105764	G/T	splice_acceptor_variant& intron_variant	14	7.22991464	4.18E-65	4.47619973
IFI27	14:94115784	TGGCCAT GGC/T	start_lost& conservative_inframe_deletion	14	7.22991464	4.18E-65	4.47619973
IFI44	1:78662885	G/GT	frameshift_variant	18	3.62858894	1.20E-30	3.63485564
OAS2	12:113010483	A/G	stop_lost	19	2.51335138	7.25E-23	3.33028482
EPST11	13:42888298	T/TTCAGG	frameshift_variant	17	3.22174861	6.81E-18	3.27200626
ACE	17:63486300	C/A	stop_gained	4	9.10262032	0.00107677	3.11768804
MSR1	8:16186158	C/T	splice_donor_variant& intron_variant	4	3.28217749	5.35E-04	0.73409481
COL6A2	21:46125455	A/AC	splice_acceptor_variant& intron_variant	1	3.28721175	7.06E-18	0.34946627
SIGLEC10	19:51417359	C/T	splice_acceptor_variant& intron_variant	2	1.88542826	1.09E-08	-0.0807563
RETSAT	2:85350974	TA/T	frameshift_variant	3	1.48768267	2.26E-04	-0.1410527
CC2D2A	4:15480736	C/T	stop_gained	1	1.84782388	4.07E-04	-0.4083765

305


306 **Table 7 : Identification of Key Disease-Associated Genes Based on Z-Score Values**

307

308 **Dynamics of Gene Expression in Pre- and Post-Treatment Time Series**

309 The temporal changes in expression levels for selected genes were assessed. For each gene group, log2 fold changes were
 310 calculated at three time points: pre-treatment, 1 month, and 3 months post-treatment. Significant changes in expression
 311 levels were observed when comparing pre-treatment samples to those from healthy subjects, particularly for the genes
 312 ACE, CC2D2A, COL6A2, EPST11, IFI27, IFI44, MSR1, OAS2, RETSAT, and SIGLEC10 (Figure 2a). Overall, many
 313 genes exhibited significant temporal changes in expression levels compared to pre-treatment. For example, EPST11 was
 314 strongly upregulated before treatment, with this upregulation alleviated after one month and further reduced after three

315 months. A similar pattern was observed for IFI27, IFI44, and CC2D2A. Conversely, ACE and RETSAT exhibited a
316 reverse trend, with marked suppression of expression before and one month post-treatment, followed by recovery after
317 three months. PTPRJ and SIGLEC10 showed reduced expression at 1 and 3 months post-treatment compared to healthy
318 subjects, while OR13C8 and SLC35G had a read count of 0 in both patients and healthy subjects. Enrichment analysis
319 revealed that GO terms related to the regulation of immune response, leukocyte-mediated immunity, and cell killing were
320 enriched in pre-treatment samples but were no longer enriched at 1 and 3 months post-treatment (Figure 2b). In contrast,
321 GO terms involved in chemotaxis, cell migration, and cell differentiation were newly enriched at 1 and 3 months post-
322 treatment. The pre-treatment samples were plotted in the third quadrant, while the 1- and 3-month post-treatment samples
323 were plotted in the first quadrant (Figure 2c). A heatmap identified genes with high loading on the negative axis of PC1,
324 including BFAR, XG, RCE1, and COL18A1 (Figure 2d). For each gene showing a recovery trend after 3 months, the
325 OMIM database was used to search for causative genes with phenotypes similar to those observed in the patient. The
326 results indicated that a decrease in ACE led to an increase in bradykinin, contributing to the development of angioedema
327 [14,15].
328



329

330 Figure 2. Analysis of Time-Series Changes in Gene Expression Levels and Pathway Enrichment

331 Analysis of Changes in Gene Expression Levels and Enriched Pathways Using Patient Samples Collected at Pre-
332 treatment, 1 Month, and 3 Month Time Points. a) Comparison of expression levels of candidate target genes at each time
333 point. Three asterisks indicate an adjusted p-value of less than 0.01, representing a significant difference from the healthy
334 group. b) Transition of enriched GO terms at each time point, representing Biological Process (BP), Molecular Function
335 (MF), and Cellular Component (CC). c) PCA plot using RNA-seq data from healthy subjects and patients at each time
336 point. d) PCA for each gene. e) Heatmap displaying loading values, showing PC1 to PC5, clustered in rows.

337

338 **Exploration of upstream and master regulators of the ACE gene by IPA**

339 Analysis of the dynamics of gene expression in pre- and post-treatment time series suggested a relationship between the
340 ACE gene and patients with the disease. To further explore this, we investigated the relationship between the ACE gene
341 and the disease by visualizing upstream regulators and causal networks using IPA for the ACE gene. When we searched
342 for upstream regulators of ACE using pre-treatment RNA-seq data, we found that the IFNG gene had the highest
343 Activation z-score of 4.403 (Figure S5a). Similarly, in the causal network's Activation z-scores, the IFNG gene also had
344 the highest Activation z-score of 4.217 (Figure S5b). The network visualization showed an interaction from IFNG in the
345 extracellular space to ACE in the plasma membrane (Figure S5c). To further investigate the association between IFNG
346 and this patient, a drill-down analysis using IPA for the IFNG gene identified an association with idiopathic eosinophilia
347 [16]. Pathways enriched in IPA for this disease, including pathway diagrams for RNA virus infection and network
348 diagrams for Angioedema, which are suggested to be relevant to the disease pathogenesis, are provided in the
349 Supplementary Information (Figures S6, 7).

350

351 **Discussion**

352 The aim of this study was to identify the pathological factors in patients diagnosed with HE/Gleich syndrome of
353 unknown etiology using WGS and RNA-seq analysis.

354 The patient presented with clinical symptoms consistent with Gleich's syndrome, including marked eosinophilia
355 exceeding 5000/ μ L at its peak, periodic fever, and recurrent edema and urticaria. However, the patient also exhibited a
356 generalized skin rash with pathological findings of vasculitis and pigmentation, transient neutrophil-predominant
357 leukemoid reactions associated with fever, markedly elevated CRP levels, and splenomegaly. These findings are not
358 commonly observed in Gleich's syndrome, but similar cases have been reported [17–19]. Although this patient did not
359 meet the strict diagnostic criteria for HES, as eosinophilic infiltration was not clearly demonstrated in various organ

360 assessments, some consider Gleich syndrome itself to be a broader category of HES [20]. This reflects the fact that the
361 disease concepts of HE and HES are not fully defined, and their classification has evolved over time. In any case, the
362 patient exhibited a very advanced and dramatic clinical presentation, with no spontaneous remission for more than 6
363 months, leading to a diagnosis of severe Gleich syndrome after all other differential diagnoses were ruled out.

364 Gleich syndrome is a rare disease with no currently approved or clearly defined diagnostic criteria, and to date,
365 fewer than 100 adult cases have been reported [21]. Nevertheless, patients with Gleich syndrome typically present with
366 homogeneous clinical symptoms and well-characterized laboratory findings, suggesting that the disease should be
367 considered a distinct eosinophilic disorder, likely caused by a common pathogenic mechanism [19].
368 In cases with clear and intense symptoms, as in this case, even a small number of disease samples are likely to lead to the
369 identification of some pathological factors by Multi-Omics Analysis, which is very significant for the purpose of
370 elucidating the pathology of rare diseases. This is very significant for the purpose of elucidating the pathology of rare
371 diseases.

372 In the disease variant analysis using WGS data, deletion mutations associated with FOXO1, PRDM16, SPAST,
373 ITSN1, and DLGAP2 were identified in AnnotSV as variants with an ACMG class >3 and a LOEUF_bin score of 0. The
374 FOXO family, including FOXO1, is known to upregulate various pro-inflammatory cytokines, including interleukin (IL)-
375 1 β , IL-9, Toll-like receptor (TLR)1, and TLR4 [22]. FOXO1 is activated by bacteria in dendritic cells (DCs) and plays
376 crucial roles in immune responses, including promoting DC phagocytosis, migration, homing to lymph nodes,
377 stimulating T cells, activating B cells, and enhancing antibody production [23]. The PRDM16 gene regulates adipocyte
378 differentiation and thermogenesis, making it a promising target for the treatment of obesity and diabetes [24,25]. It is also
379 involved in the development and function of endothelial cells and vascular smooth muscle cells in arteries and plays a
380 critical role in the regulation of inflammatory responses [26]. ITSN1 is known to play a crucial role in pathogen uptake
381 through clathrin-mediated endocytosis (CME) and also functions as a scaffolding protein in cell signaling pathways [27].
382 This may allow ITSN1 to influence eosinophil activation and function. SPAST and DLGAP2 are both genes that are
383 critical for maintaining the health and function of the nervous system and have not been reported to be involved in
384 eosinophil-related diseases.

385 SNPnexus-based analysis identified PTPRJ, SLC4A1, FGFR4, and C1GALT1C1 as genes with corresponding
386 mutations classified as pathogenic in the ClinVar annotations. PTPRJ and FGFR4 are implicated in the development and
387 susceptibility to various cancers [28–37]. Eosinophils are known to play an anti-tumor role in melanoma, gastric,
388 colorectal, oral, and prostate cancers, while they are associated with poor prognosis in Hodgkin's lymphoma and cervical

389 cancer [38]. The relationship between eosinophilia-associated SNPs and tumor grade warrants further investigation.
390 SLC4A1 (Solute Carrier Family 4 Member 1) encodes an anion exchange protein critical for erythrocyte function, and
391 mutations in SLC4A1 have been shown to impair erythrocyte membrane stability [39]. However, no involvement in
392 eosinophil-related diseases has been reported to date. C1GALT1C1 is crucial for glycosylation, and patients with Tn
393 polyagglutination syndrome (TNPS) are known to carry an aspartic acid to glutamic acid mutation at position 131 [40].

394 Confirmation of mutations by exon using WANNVAR identified a series of mutations across diverse genes,
395 including APC, OR13C8, PCDH17, GSPT1, MED1, SLC35G4, and MADCAM1. The APC gene has been associated
396 with familial colorectal adenomatosis, as documented on the ClinVar website [41]. PCDH17 is primarily involved in
397 neuronal adhesion and synapse formation [42]. GSPT1 is a gene implicated in cell proliferation and translation
398 regulation. MED1 functions as a transcriptional regulator in the nucleus, controlling the expression of specific genes
399 [43,44]. MADCAM1, a cell adhesion molecule, is expressed in high endothelial venules, facilitating immune cell
400 migration from the bloodstream to the gut [45]. However, no studies have been identified that directly link any of these
401 genes to eosinophilia.

402 In the analysis of DEGs between patients and healthy controls from RNA-seq data, the Biological Process
403 category of GO term enrichment analysis showed enrichment in 'regulation of response to biotic stimulus,' 'response to
404 virus,' and GO terms related to 'regulation of viral processes.' Hypereosinophilia refers to an increase in the number of
405 eosinophils in the blood, observed in response to various biotic stimuli such as infections, allergic reactions, viruses, and
406 certain autoimmune diseases [46–48]. Eosinophils are a type of white blood cell that plays a crucial role in the body's
407 immune response to parasites and allergens. Their regulation and proliferation are known to be influenced by various
408 cytokines and transcription factors, most notably interleukin-5 (IL-5) [49]. The identification of several genes enriched
409 by biotic stimuli in this patient also reflects a pathology that results in a dramatic systemic clinical presentation.

410 In addition, within the Molecular Function category, several GO terms were enriched for carbohydrate binding,
411 monosaccharide binding, glucose binding, proteoglycan binding, and glycan-related genes, such as 'pentosyltransferase
412 activity.' Glycosylation is a common post-translational modification of proteins and lipids and serves as a critical
413 recognition determinant in cell-immune system interactions. Immune and stromal cells are equipped with glycan-binding
414 proteins (GBPs) that sense and decode diverse glycans [50,51]. This network of glycans and GBPs is crucial for the
415 recognition of pathogens and the regulation of inflammatory and autoimmune responses, with alterations in the cellular
416 glycome ultimately leading to pathological phenotypes [52–54]. C1GALT1C1 (rs17261572), also known as Cosmc,
417 identified in variant analysis, galactosylates Tn antigen (GalNAc α 1-Ser/Thr-R) during the biosynthesis of mucin-type O-

418 glycans to core 1 Gal β 1-3GalNAc α 1-Ser/Thr (T antigen) [55] (Figure S8). Given that glycans function as drug
419 recognition markers, the potential involvement of glycan-related genes in drug regulation has been investigated in public
420 database analyses [56]. The relationship between rs17261572 on C1GALT1C1 and HE/Gleich syndrome, as well as its
421 connection to other glycan-related genes, warrants further investigation.

422 The Z-score values derived from WGS annotation impact, along with the ranking of DEGs and PPI network
423 analysis from RNA-seq data, identified IFI27, OAS2, and ACE as key candidate genes. In this case, the expression levels
424 of these genes were variable compared to healthy subjects and showed a recovery trend after treatment. It is well
425 established that a reduction in ACE leads to an increase in bradykinin, which contributes to the development of
426 angioedema [57,58]. Bradykinin itself induces angioedema [59] and further increases phospholipase A2 activity,
427 enhances arachidonic acid metabolism, and triggers a wide range of inflammatory responses [60]. Additionally, large
428 amounts of bradykinin have been reported to recruit eosinophils [60,61]. In this patient, who presented with severe
429 systemic inflammation in addition to edema, ACE was found to play a major role as a pathological factor. The patient
430 achieved a good state of remission with oral prednisolone treatment, not only due to the general anti-inflammatory effects
431 of corticosteroids but also because corticosteroids have been suggested to directly restore ACE expression [62], which
432 may have contributed to the improvement in the condition.

433 Notably, there is a case report of a patient with congenital ACE deficiency presenting with recurrent angioedema
434 [63]. This finding further supports the involvement of ACE as a pathological factor in diseases characterized by
435 angioedema (Figure 3). However, in the present case, no mutation in the ACE gene itself critically defines a loss of
436 expression, suggesting that an alteration in an upstream factor leading to reduced ACE expression may be involved.


437 PRDM16, a gene with a confirmed structural abnormality in this case, has been shown to reduce ACE mRNA
438 expression in the systemic RAAS when conditionally knocked out (CKO) in the heart, although the detailed mechanism
439 remains unclear [64]. While ACE expression in the intrarenal RAAS is compensated for in this CKO model, it is
440 plausible that the PRDM16 mutation observed in this patient results in a systemic reduction in ACE expression. However,
441 the direct mechanism by which PRDM16 mutations lead to reduced ACE expression is not fully understood and warrants
442 further investigation.

443 Upstream regulators and causal networks of ACE were investigated using IPA to explore their relationship with
444 the pathogenesis in greater detail. The IFNG gene was identified as an upstream regulator of ACE. Previous studies have
445 reported that human IFNG protein increases the expression of ACE mRNA in NB4 cells and enhances the expression of
446 ACE protein on the cell surface of cultured human peripheral blood monocytes [65]. Additionally, IFNG has been

447 detected in the supernatant of cultured peripheral blood mononuclear cells from patients with idiopathic eosinophilia,
448 suggesting its involvement in the disease's pathogenesis [66]. Further research is needed to elucidate these mechanisms in
449 more detail.

450 This study has certain limitations. While Multi-Omics analyses using whole genome sequencing (WGS) and
451 RNA sequencing (RNA-seq) have advanced our understanding of the pathogenesis of HE/Gleich syndrome at the genetic
452 and gene expression levels, these approaches must be supplemented with protein-level analyses and in vivo model-based
453 studies. Confirming blood levels of bradykinin and ACE would further substantiate the pathogenesis of this condition.
454 Moreover, other factors influencing ACE expression need to be investigated, and detailed mechanisms must be
455 elucidated. Gene expression data alone do not adequately capture post-translational modifications, protein interactions, or
456 functional dynamics within cells and tissues. In vivo models can provide a more comprehensive understanding of disease
457 mechanisms within a physiological context. Therefore, future research should incorporate proteomic analyses, gene
458 editing techniques, and animal models.

459



460

461 Figure 3 The role of ACE as a pathogenic factor in a type of HE/Gleich syndrome

462 This figure illustrates the pathway by which a PRDM16 mutation leads to pathogenic outcomes in HE/Gleich Syndrome.
463 The mutation downregulates ACE expression, resulting in elevated bradykinin levels. This triggers the arachidonic acid
464 cascade, which contributes to both angioedema and severe inflammation. Additionally, IFN- γ levels influence ACE
465 expression, further exacerbating these processes.

466

467 **Conclusion**

468 The aim of this study was to analyze whole genome sequencing (WGS) and RNA sequencing (RNA-seq) data from
469 patient-derived samples of individuals diagnosed with severe HE/Gleich syndrome of unknown etiology, and to identify
470 the underlying pathological factors. The analysis revealed that ACE plays a significant role in the condition,
471 demonstrating the utility of genomic analysis for understanding this disease. Specifically, the study indicated that reduced
472 ACE expression may result from a complex interplay of factors, including PRDM16 gene mutations and altered
473 expression of IFN γ , which may contribute to the development of angioedema and marked inflammation. The findings of
474 this study will enhance the understanding of the pathomechanisms of HE/Gleich syndrome and inform the development
475 of new therapeutic strategies in the future.

476 **Supplementary Information**

477

478 **Data Availability**

479

480 **Acknowledgements**

481 We sincerely thank the patients who participated in this study for their invaluable cooperation. I also wish to express our
482 deepest appreciation to Dr. Hirokazu Muraoka for his extensive guidance and support throughout the entirety of this
483 study. His contributions spanned from the conceptualization of the research, the collection of blood samples, and the
484 acquisition of WGS and RNA-seq data, to the writing, editing, and discussion of the manuscript.

485

486 **Conflict of interest statement**

487 The authors declare that there are no conflicts.

488

489 **Reference**

- 490 (1) Roufosse, F.; Weller, P. F. *Journal of Allergy and Clinical Immunology* **2010**, *126*, 39–44.
491 doi:10.1016/j.jaci.2010.04.011
- 492 (2) Rothenberg, M. E. *New England Journal of Medicine* **1998**, *338*, 1592–1600.
493 doi:10.1056/NEJM199805283382206
- 494 (3) Valent, P.; Klion, A. D.; Horny, H. P.; Roufosse, F.; Gotlib, J.; Weller, P. F.; Hellmann, A.; Metzgeroth, G.;
495 Leiferman, K. M.; Arock, M.; Butterfield, J. H.; Sperr, W. R.; Sotlar, K.; Vandenberghe, P.; Haferlach, T.;
496 Simon, H. U.; Reiter, A.; Gleich, G. J. *Journal of Allergy and Clinical Immunology* **2012**, *130*, 607–612.e9.
497 doi:10.1016/j.jaci.2012.02.019
- 498 (4) Gleich, G. J.; Schroeter, A. L.; Marcoux, J. P.; Sachs, M. I.; O’Connell, E. J.; Kohler, P. F. *Trans Assoc Am*
499 *Physicians* **1984**, *97*, 25–32. doi:10.1056/NEJM198406213102501
- 500 (5) Cools, J.; DeAngelo, D. J.; Gotlib, J.; Stover, E. H.; Legare, R. D.; Cortes, J.; Kutok, J.; Clark, J.; Galinsky,
501 I.; Griffin, J. D.; Cross, N. C. P.; Tefferi, A.; Malone, J.; Alam, R.; Schrier, S. L.; Schmid, J.; Rose, M.;
502 Vandenberghe, P.; Verhoef, G.; Boogaerts, M.; Wlodarska, I.; Kantarjian, H.; Marynen, P.; Coutre, S. E.;
503 Stone, R.; Gilliland, D. G. *New England Journal of Medicine* **2003**, *348*, 1201–1214.

- 504 doi:10.1056/NEJMOA025217/ASSET/02DE2273-F36A-40F0-A786-
505 276BD835B728/ASSETS/IMAGES/LARGE/NEJMOA025217_F5.JPG
- 506 (6) Simon, H.-U.; Plötz, S. G.; Dummer, R.; Blaser, K. *New England Journal of Medicine* **1999**, *341*, 1112–
507 1120. doi:10.1056/NEJM199910073411503/ASSET/F1312766-756C-4DAD-BB7E-
508 B527821BB498/ASSETS/IMAGES/LARGE/NEJM199910073411503_T4.JPG
- 509 (7) Van El, C. G.; Cornel, M. C.; Borry, P.; Hastings, R. J.; Fellmann, F.; Hodgson, S. V.; Howard, H. C.;
510 Cambon-Thomsen, A.; Knoppers, B. M.; Meijers-Heijboer, H.; Scheffer, H.; Tranebjaerg, L.; Dondorp, W.;
511 De Wert, G. M. W. R. *European Journal of Human Genetics* *2013* **21**:6 **2013**, *21*, 580–584.
512 doi:10.1038/ejhg.2013.46
- 513 (8) Ashley, E. A.; Butte, A. J.; Wheeler, M. T.; Chen, R.; Klein, T. E.; Dewey, F. E.; Dudley, J. T.; Ormond, K.
514 E.; Pavlovic, A.; Morgan, A. A.; Pushkarev, D.; Neff, N. F.; Hudgins, L.; Gong, L.; Hodges, L. M.; Berlin,
515 D. S.; Thorn, C. F.; Sangkuhl, K.; Hebert, J. M.; Woon, M.; Sagreiya, H.; Whaley, R.; Knowles, J. W.;
516 Chou, M. F.; Thakuria, J. V.; Rosenbaum, A. M.; Zaranek, A. W.; Church, G. M.; Greely, H. T.; Quake, S.
517 R.; Altman, R. B. *The Lancet* **2010**, *375*, 1525–1535. doi:10.1016/S0140-6736(10)60452-7
- 518 (9) Lupski, J. R.; Reid, J. G.; Gonzaga-Jauregui, C.; Rio Deiros, D.; Chen, D. C. Y.; Nazareth, L.; Bainbridge,
519 M.; Dinh, H.; Jing, C.; Wheeler, D. A.; McGuire, A. L.; Zhang, F.; Stankiewicz, P.; Halperin, J. J.; Yang, C.;
520 Gehman, C.; Guo, D.; Irikat, R. K.; Tom, W.; Fantin, N. J.; Muzny, D. M.; Gibbs, R. A. *New England*
521 *Journal of Medicine* **2010**, *362*, 1181–1191.
522 doi:10.1056/NEJMOA0908094/SUPPL_FILE/NEJMOA0908094_DISCLOSURES.PDF
- 523 (10) Roach, J. C.; Glusman, G.; Smit, A. F. A.; Huff, C. D.; Hubley, R.; Shannon, P. T.; Rowen, L.; Pant, K. P.;
524 Goodman, N.; Bamshad, M.; Shendure, J.; Drmanac, R.; Jorde, L. B.; Hood, L.; Galas, D. J. *Science (1979)*
525 **2010**, *328*, 636–639. doi:10.1126/SCIENCE.1186802/SUPPL_FILE/ROACH-SOM.PDF
- 526 (11) Lee, J. S.; Seo, H.; Im, K.; Park, S. N.; Kim, S. M.; Lee, E. K.; Kim, J. A.; Lee, J. H.; Kwon, S.; Kim, M.;
527 Koh, I.; Hwang, S.; Park, H. W.; Kang, H. R.; Park, K. S.; Kim, J. H.; Lee, D. S. *PLoS One* **2017**, *12*,
528 e0185602. doi:10.1371/JOURNAL.PONE.0185602
- 529 (12) Andersen, C. L.; Nielsen, H. M.; Kristensen, L. S.; Søgaaard, A.; Vikeså, J.; Jønson, L.; Nielsen, F. C.;
530 Hasselbalch, H.; Bjerrum, O. W.; Punj, V.; Grønbaek, K.; Andersen, C. L.; Nielsen, H. M.; Kristensen, L. S.;

- 531 Søggaard, A.; Vikeså, J.; Jønson, L.; Nielsen, F. C.; Hasselbalch, H.; Bjerrum, O. W.; Punj, V.; Grønbaek, K.
532 *Oncotarget* **2015**, *6*, 40588–40597. doi:10.18632/ONCOTARGET.5845
- 533 (13) Blake, J. A.; Christie, K. R.; Dolan, M. E.; Drabkin, H. J.; Hill, D. P.; Ni, L.; Sitnikov, D.; Burgess, S.;
534 Buza, T.; Gresham, C.; McCarthy, F.; Pillai, L.; Wang, H.; Carbon, S.; Dietze, H.; Lewis, S. E.; Mungall, C.
535 J.; Munoz-Torres, M. C.; Feuermann, M.; Gaudet, P.; Basu, S.; Chisholm, R. L.; Dodson, R. J.; Fey, P.; Mi,
536 H.; Thomas, P. D.; Muruganujan, A.; Poudel, S.; Hu, J. C.; Aleksander, S. A.; McIntosh, B. K.; Renfro, D.
537 P.; Siegele, D. A.; Attrill, H.; Brown, N. H.; Tweedie, S.; Lomax, J.; Osumi-Sutherland, D.; Parkinson, H.;
538 Roncaglia, P.; Lovering, R. C.; Talmud, P. J.; Humphries, S. E.; Denny, P.; Campbell, N. H.; Foulger, R. E.;
539 Chibucos, M. C.; Giglio, M. G.; Chang, H. Y.; Finn, R.; Fraser, M.; Mitchell, A.; Nuka, G.; Pesseat, S.;
540 Sangrador, A.; Scheremetjew, M.; Young, S. Y.; Stephan, R.; Harris, M. A.; Oliver, S. G.; Rutherford, K.;
541 Wood, V.; Bahler, J.; Lock, A.; Kersey, P. J.; McDowall, M. D.; Staines, D. M.; Dwinell, M.; Shimoyama,
542 M.; Laulederkind, S.; Hayman, G. T.; Wang, S. J.; Petri, V.; D'Eustachio, P.; Matthews, L.; Balakrishnan,
543 R.; Binkley, G.; Cherry, J. M.; Costanzo, M. C.; Demeter, J.; Dwight, S. S.; Engel, S. R.; Hitz, B. C.; Inglis,
544 D. O.; Lloyd, P.; Miyasato, S. R.; Paskov, K.; Roe, G.; Simison, M.; Nash, R. S.; Skrzypek, M. S.; Weng, S.;
545 Wong, E. D.; Berardini, T. Z.; Li, D.; Huala, E.; Argasinska, J.; Arighi, C.; Auchincloss, A.; Axelsen, K.;
546 Argoud-Puy, G.; Bateman, A.; Bely, B.; Blatter, M. C.; Bonilla, C.; Bougueleret, L.; Boutet, E.; Breuza, L.;
547 Bridge, A.; Britto, R.; Casals, C.; Cibrian-Uhalte, E.; Coudert, E.; Cusin, I.; Duek-Roggli, P.; Estreicher, A.;
548 Famiglietti, L.; Gane, P.; Garmiri, P.; Gos, A.; Gruaz-Gumowski, N.; Hatton-Ellis, E.; Hinz, U.; Hulo, C.;
549 Huntley, R.; Jungo, F.; Keller, G.; Laiho, K.; Lemercier, P.; Lieberherr, D.; Macdougall, A.; Magrane, M.;
550 Martin, M.; Masson, P.; Mutowo, P.; O'Donovan, C.; Pedruzzi, I.; Pichler, K.; Poggioli, D.; Poux, S.;
551 Rivoire, C.; Roechert, B.; Sawford, T.; Schneider, M.; Shypitsyna, A.; Stutz, A.; Sundaram, S.; Tognolli, M.;
552 Wu, C.; Xenarios, I.; Chan, J.; Kishore, R.; Sternberg, P. W.; Van Auken, K.; Muller, H. M.; Done, J.; Li, Y.;
553 Howe, D.; Westerfeld, M. *Nucleic Acids Res* **2015**, *43*, D1049–D1056. doi:10.1093/NAR/GKU1179
- 554 (14) Ghebrehiwet, B.; Joseph, K.; Kaplan, A. P. *Frontiers in Allergy* **2024**, *5*, 1302605.
555 doi:10.3389/FALGY.2024.1302605/BIBTEX
- 556 (15) Straka, B. T.; Ramirez, C. E.; Byrd, J. B.; Stone, E.; Woodard-Grice, A.; Nian, H.; Yu, C.; Banerji, A.;
557 Brown, N. J. *Journal of Allergy and Clinical Immunology* **2017**, *140*, 242-248.e2.
558 doi:10.1016/j.jaci.2016.09.051





- 559 (16) Simon, H.-U.; Plötz, S. G.; Dummer, R.; Blaser, K. *New England Journal of Medicine* **1999**, *341*, 1112–
560 1120. doi:10.1056/NEJM199910073411503/ASSET/F1312766-756C-4DAD-BB7E-
561 B527821BB498/ASSETS/IMAGES/LARGE/NEJM199910073411503_T4.JPG
- 562 (17) Basso, J. R.; Bizinoto, L. G. Z.; Limone, G. A.; Enokihara, M. M. S. S.; Do Espirito-Santo Filho, K.;
563 Fonseca, A. R.; Agondi, R. C.; de Gois, A. F. T.; Cunha, L. L. *Brazilian Journal of Medical and Biological*
564 *Research* **2021**, *54*, e10745. doi:10.1590/1414-431X202010745
- 565 (18) Mormile, I.; Petraroli, A.; Loffredo, S.; Rossi, F. W.; Mormile, M.; Mastro, A. Del; Spadaro, G.; de Paulis,
566 A.; Bova, M. *Journal of Clinical Medicine* *2021*, *Vol. 10*, *Page 1442* **2021**, *10*, 1442.
567 doi:10.3390/JCM10071442
- 568 (19) Khoury, P.; Herold, A.; Alpaugh, A.; Dinerman, E.; Holland-Thomas, N.; Stoddard, J.; Gurprasad, S.; Maric,
569 I.; Simakova, O.; Schwartz, L. B.; Fong, J.; Richard Lee, C. C.; Xi, L.; Wang, Z.; Raffeld, M.; Klion, A. D.
570 *Haematologica* **2015**, *100*, 300–307. doi:10.3324/HAEMATOL.2013.091264
- 571 (20) Valent, P.; Klion, A. D.; Horny, H. P.; Roufosse, F.; Gotlib, J.; Weller, P. F.; Hellmann, A.; Metzgeroth, G.;
572 Leiferman, K. M.; Arock, M.; Butterfield, J. H.; Sperr, W. R.; Sotlar, K.; Vandenberghe, P.; Haferlach, T.;
573 Simon, H. U.; Reiter, A.; Gleich, G. J. *Journal of Allergy and Clinical Immunology* **2012**, *130*, 607-612.e9.
574 doi:10.1016/j.jaci.2012.02.019
- 575 (21) Mormile, I.; Petraroli, A.; Loffredo, S.; Rossi, F. W.; Mormile, M.; Mastro, A. Del; Spadaro, G.; de Paulis,
576 A.; Bova, M. *Journal of Clinical Medicine* *2021*, *Vol. 10*, *Page 1442* **2021**, *10*, 1442.
577 doi:10.3390/JCM10071442
- 578 (22) Kim, M. E.; Kim, D. H.; Lee, J. S. *International Journal of Molecular Sciences* *2022*, *Vol. 23*, *Page 11877*
579 **2022**, *23*, 11877. doi:10.3390/IJMS231911877
- 580 (23) Cabrera-Ortega, A. A.; Feinberg, D.; Liang, Y.; Rossa, C.; Graves, D. T. *Critical Reviews & Trade; in*
581 *Immunology* **2017**, *37*, 1–13. doi:10.1615/CRITREVIMMUNOL.2017019636
- 582 (24) Seale, P.; Conroe, H. M.; Estall, J.; Kajimura, S.; Frontini, A.; Ishibashi, J.; Cohen, P.; Cinti, S.; Spiegelman,
583 B. M. *J Clin Invest* **2011**, *121*, 96–105. doi:10.1172/JCI44271
- 584 (25) Jiang, N.; Yang, M.; Han, Y.; Zhao, H.; Sun, L. *Front Pharmacol* **2022**, *13*, 870250.
585 doi:10.3389/FPHAR.2022.870250/BIBTEX

- 586 (26) Thompson, M.; Sakabe, M.; Verba, M.; Hao, J.; Meadows, S. M.; Lu, Q. R.; Xin, M. *Front Physiol* **2023**,
587 *14*, 1165379. doi:10.3389/FPHYS.2023.1165379/BIBTEX
- 588 (27) Gerasymchuk, D.; Hubiernatorova, A.; Domanskyi, A. *Front Neurol* **2020**, *11*, 549006.
589 doi:10.3389/FNEUR.2020.549006/BIBTEX
- 590 (28) Iuliano, R.; Le Pera, I.; Cristofaro, C.; Baudi, F.; Arturi, F.; Pallante, P. L.; Martelli, M. L.; Trapasso, F.;
591 Chiariotti, L.; Fusco, A. *Oncogene* *2004* **23**:52 **2004**, *23*, 8432–8438. doi:10.1038/sj.onc.1207766
- 592 (29) Jaakkola, S.; Salmikangas, P.; Nylund, S.; Lehtovirta, P.; Nevanlinna, H.; Partanen, J.; Armstrong, E.;
593 Pyrhönen, S. *Int J Cancer* **1993**, *54*, 378–382. doi:10.1002/IJC.2910540305
- 594 (30) Leung, H. Y.; Gullick, W. J.; Lemoine, N. R. *Int J Cancer* **1994**, *59*, 667–675. doi:10.1002/IJC.2910590515
- 595 (31) Sahadevan, K.; Darby, S.; Leung, H. Y.; Mathers, M. E.; Robson, C. N.; Gnanapragasam, V. J. *J Pathol*
596 **2007**, *213*, 82–90. doi:10.1002/PATH.2205
- 597 (32) Streit, S.; Mestel, D. S.; Schmidt, M.; Ullrich, A.; Berking, C. *British Journal of Cancer* *2006* **94**:12 **2006**,
598 *94*, 1879–1886. doi:10.1038/sj.bjc.6603181
- 599 (33) Cancer Progression and Tumor Cell Motility Are Associated with the FGFR4 Arg388 Allele | Cancer
600 Research | American Association for Cancer Research
601 [https://aacrjournals.org/cancerres/article/62/3/840/509605/Cancer-Progression-and-Tumor-Cell-Motility-](https://aacrjournals.org/cancerres/article/62/3/840/509605/Cancer-Progression-and-Tumor-Cell-Motility-Are)
602 [Are](https://aacrjournals.org/cancerres/article/62/3/840/509605/Cancer-Progression-and-Tumor-Cell-Motility-Are) (accessed Aug 16, 2024)
- 603 (34) Matakidou, A.; El Galta, R.; Rudd, M. F.; Webb, E. L.; Bridle, H.; Eisen, T.; Houlston, R. S. *British Journal*
604 *of Cancer* *2007* **96**:12 **2007**, *96*, 1904–1907. doi:10.1038/sj.bjc.6603816
- 605 (35) Spinola, M.; Leani, V.; Pignatiello, C.; Conti, B.; Ravagnani, F.; Pastorino, U.; Dragani, T. A.
606 <https://doi.org/10.1200/JCO.2005.17.350> **2016**, *23*, 7307–7311. doi:10.1200/JCO.2005.17.350
- 607 (36) Wang, J.; Stockton, D. W.; Ittmann, M. *Clinical Cancer Research* **2004**, *10*, 6169–6178. doi:10.1158/1078-
608 0432.CCR-04-0408
- 609 (37) Thussbas, C.; Nahrig, J.; Streit, S.; Bange, J.; Kriner, M.; Kates, R.; Ulm, K.; Kiechle, M.; Hoefler, H.;
610 Ullrich, A.; Harbeck, N. <https://doi.org/10.1200/JCO.2005.04.8587> **2016**, *24*, 3747–3755.
611 doi:10.1200/JCO.2005.04.8587
- 612 (38) Varricchi, G.; Galdiero, M. R.; Loffredo, S.; Lucarini, V.; Marone, G.; Mattei, F.; Marone, G.; Schiavoni, G.
613 *Oncoimmunology* **2018**, *7*. doi:10.1080/2162402X.2017.1393134

- 614 (39) Bruce, L. J.; Robinson, H. C.; Guizouarn, H.; Borgese, F.; Harrison, P.; King, M. J.; Goede, J. S.; Coles, S.
615 E.; Gore, D. M.; Lutz, H. U.; Ficarella, R.; Layton, D. M.; Iolascon, A.; Ellory, J. C.; Stewart, G. W. *Nature*
616 *Genetics* 2005 37:11 **2005**, 37, 1258–1263. doi:10.1038/ng1656
- 617 (40) Ju, T.; Cummings, R. D. *Proc Natl Acad Sci U S A* **2002**, 99, 16613–16618.
618 doi:10.1073/PNAS.262438199/ASSET/E7D75E83-13F7-4461-A8AA-
619 B2B085A2E14B/ASSETS/GRAPHIC/PQ2624381004.JPEG
- 620 (41) VCV001050412.3 - ClinVar - NCBI <https://www.ncbi.nlm.nih.gov/clinvar/variation/1050412/> (accessed
621 Aug 16, 2024)
- 622 (42) Abrahams, B. S.; Tentler, D.; Perederiy, J. V.; Oldham, M. C.; Coppola, G.; Geschwind, D. H. *Proc Natl*
623 *Acad Sci U S A* **2007**, 104, 17849–17854.
624 doi:10.1073/PNAS.0706128104/SUPPL_FILE/06128TABLE6.PDF
- 625 (43) Hoshino, S.; Imai, M.; Mizutani, M.; Kikuchi, Y.; Hanaoka, F.; Ui, M.; Katada, T. *Journal of Biological*
626 *Chemistry* **1998**, 273, 22254–22259. doi:10.1074/jbc.273.35.22254
- 627 (44) Kikuchi, Y.; Shimatake, H.; Kikuchi, A. *EMBO J* **1988**, 7, 1175–1182. doi:10.1002/J.1460-
628 2075.1988.TB02928.X
- 629 (45) Arihiro, S.; Ohtani, H.; Suzuki, M.; Murata, M.; Ejima, C.; Oki, M.; Kinouchi, Y.; Fukushima, K.; Sasaki,
630 I.; Nakamura, S.; Matsumoto, T.; Torii, A.; Toda, G.; Nagura, H. *Pathol Int* **2002**, 52, 367–374.
631 doi:10.1046/J.1440-1827.2002.01365.X
- 632 (46) Macchia, I.; La Sorsa, V.; Urbani, F.; Moretti, S.; Antonucci, C.; Afferni, C.; Schiavoni, G. *Front Immunol*
633 **2023**, 14, 1170035. doi:10.3389/FIMMU.2023.1170035/BIBTEX
- 634 (47) Thomsen, G. N.; Christoffersen, M. N.; Lindegaard, H. M.; Davidsen, J. R.; Hartmeyer, G. N.; Assing, K.;
635 Mortz, C. G.; Martin-Iguacel, R.; Møller, M. B.; Kjeldsen, A. D.; Havelund, T.; El Fassi, D.; Broesby-
636 Olsen, S.; Maiborg, M.; Johansson, S. L.; Andersen, C. L.; Vestergaard, H.; Bjerrum, O. W. *Front Oncol*
637 **2023**, 13, 1193730. doi:10.3389/FONC.2023.1193730/BIBTEX
- 638 (48) Klion, A. D. *Hematology* **2015**, 2015, 92–97. doi:10.1182/ASHEDUCATION-2015.1.92
- 639 (49) Kouro, T.; Takatsu, K. *Int Immunol* **2009**, 21, 1303–1309. doi:10.1093/INTIMM/DXP102
- 640 (50) Alves, I.; Fernandes, Â.; Santos-Pereira, B.; Azevedo, C. M.; Pinho, S. S. *FEBS Lett* **2022**, 596, 1485–1502.
641 doi:10.1002/1873-3468.14347

- 642 (51) Pinho, S. S.; Alves, I.; Gaifem, J.; Rabinovich, G. A. *Cellular & Molecular Immunology* **2023**, *20*:10 **2023**,
643 20, 1101–1113. doi:10.1038/s41423-023-01074-1
- 644 (52) Ohtsubo, K.; Marth, J. D. *Cell* **2006**, *126*, 855–867. doi:10.1016/J.CELL.2006.08.019
- 645 (53) Pinho, S. S.; Reis, C. A. *Nature Reviews Cancer* **2015**, *15*:9 **2015**, *15*, 540–555. doi:10.1038/nrc3982
- 646 (54) Rabinovich, G. A.; Croci, D. O. *Immunity* **2012**, *36*, 322–335. doi:10.1016/J.IMMUNI.2012.03.004
- 647 (55) Wang, Y.; Ju, T.; Ding, X.; Xia, B.; Wang, W.; Xia, L.; He, M.; Cummings, R. D. *Proc Natl Acad Sci U S A*
648 **2010**, *107*, 9228–9233. doi:10.1073/PNAS.0914004107/SUPPL_FILE/SFIG05.TIF
- 649 (56) Koreeda, T.; Honda, H. *Glycoconj J* **2024**, *41*, 133–149. doi:10.1007/S10719-024-10153-Y/METRICS
- 650 (57) Ghebrehiwet, B.; Joseph, K.; Kaplan, A. P. *Frontiers in Allergy* **2024**, *5*, 1302605.
651 doi:10.3389/FALGY.2024.1302605/BIBTEX
- 652 (58) Straka, B. T.; Ramirez, C. E.; Byrd, J. B.; Stone, E.; Woodard-Grice, A.; Nian, H.; Yu, C.; Banerji, A.;
653 Brown, N. J. *Journal of Allergy and Clinical Immunology* **2017**, *140*, 242–248.e2.
654 doi:10.1016/j.jaci.2016.09.051
- 655 (59) Cicardi, M.; Zuraw, B. L. *J Allergy Clin Immunol Pract* **2018**, *6*, 1132–1141.
656 doi:10.1016/J.JAIP.2018.04.022
- 657 (60) Kaplan, A. P.; Joseph, K.; Silverberg, M. *Journal of Allergy and Clinical Immunology* **2002**, *109*, 195–209.
658 doi:10.1067/MAI.2002.121316
- 659 (61) Roisman, G. L.; Lacronique, J. G.; Desmazes-Dufeu, N.; Carré, C.; Le Cae, A.; Dusser, D. J.
660 <https://doi.org/10.1164/ajrccm.153.1.8542147> **2012**, *153*, 381–390. doi:10.1164/AJRCCM.153.1.8542147
- 661 (62) Fishel, R. S.; Eisenberg, S.; Shai, S. Y.; Redden, R. A.; Bernstein, K. E.; Berk, B. C. *Hypertension* **1995**, *25*,
662 343–349. doi:10.1161/01.HYP.25.3.343/ASSET/9C5DA6FC-13D9-494B-97A2-
663 3A87C146FD08/ASSETS/GRAPHIC/HY0350384008.JPEG
- 664 (63) Sreeram, A. B.; Corey, J. P. <http://dx.doi.org/10.1016/S0194-59989570277-6> **1995**, *112*, 421–423.
665 doi:10.1016/S0194-59989570277-6
- 666 (64) Kang, J. O.; Ha, T. W.; Jung, H. U.; Lim, J. E.; Oh, B. *PLoS One* **2022**, *17*, e0267938.
667 doi:10.1371/JOURNAL.PONE.0267938
- 668 (65) Obeid, D.; Nguyen, J.; Lesavre, P.; Bauvois, B. *Oncogene* **2007**, *26*:1 **2006**, *26*, 102–110.
669 doi:10.1038/sj.onc.1209779

670 (66) Simon, H.-U.; Plötz, S. G.; Dummer, R.; Blaser, K. *New England Journal of Medicine* **1999**, *341*, 1112–
671 1120. doi:10.1056/NEJM199910073411503/ASSET/F1312766-756C-4DAD-BB7E-
672 B527821BB498/ASSETS/IMAGES/LARGE/NEJM199910073411503_T4.JPG
673



PRDM16↓(mutation)



ACE↓



Bradykinin↑↑



arachidonic acid cascade↑



IFN- γ changes



angioedema



severe inflammation



